Coherus Biosciences | CHRS - Чистый доход





Чистый доход Изменить Дата
AbbVie USD 695M 1.12B 2026-03
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Akebia Therapeutics USD -12.24M 12.78M 2025-12
ALKERMES USD 49.34M 33.42M 2025-12
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Amarin USD -1.22M 6.51M 2025-12
Amgen USD 1.82B 486M 2026-03
Baxter International USD -15M 1.11B 2026-03
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 7.4B 760M 2026-03
Fujifilm JPY 72.66B 6.27B 2025-12
Gilead Sciences USD 2.18B 869M 2025-12
Ironwood Pharmaceuticals USD 3.19M 457K 2024-12
Merck USD -4.24B 7.2B 2026-03
Myriad Genetics USD -7.9M 19.5M 2025-12
Pacira USD 2.92M 1.28M 2026-03
Perrigo USD -1.42B 1.43B 2025-12
Pfizer USD 2.69B 4.34B 2026-03
PTC Therapeutics USD -134.96M 150.86M 2025-12
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Teva Pharmaceutical Industries USD 369M 111M 2026-03
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03
Xencor USD -6.65M 626K 2025-12
Zoetis USD 603M 118M 2025-12